bf/NASDAQ:EDIT_icon.jpeg

COM:EDITASMEDICINE

Editas Medicine

  • Stock

Last Close

2.41

21/11 20:10

Market Cap

417.77M

Beta: -

Volume Today

1.30M

Avg: -

Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads to inherited childhood blindness. ...Show More

peer of

competitor of